Saudi German Health, the trading name of Middle East Healthcare Company, swung back to profit in the first nine months of 2026, reporting net income attributable to shareholders of SAR 104.49 million, an increase of 8.3 percent over the same period of 2025. The results, published on 8 November 2026 according to english.mubasher.info, cover the period ending 30 September 2026 and show a company that has put a painful accounting restatement behind it.
The turnaround is striking when measured quarter by quarter. The group posted a net profit of SAR 36.68 million in the third quarter, compared with a restated net loss of SAR 89.66 million in the same quarter of last year. Revenue for the quarter reached SAR 877.15 million, up 14.1 percent year on year.
What drove the recovery
The company attributed the revenue growth to the successful introduction and expansion of new revenue streams, chiefly specialized medical care and surgical services. Inpatient services revenue rose 12.2 percent, or SAR 155.8 million, over the nine months, while outpatient revenue grew 5.6 percent, adding SAR 39.1 million.
Growth in the number of surgeries performed and inpatient admissions underpinned the gains. The gross profit margin for the third quarter improved to 32.3 percent from 31.5 percent in the previous quarter, driven by a rising share of subspecialty procedures.
Discipline on overhead costs also played its part. General and administrative expenses and selling and marketing expenses fell as a percentage of revenue, and finance costs dropped by SAR 7.8 million, or 5.4 percent, over the nine-month period. Zakat expense was SAR 3.7 million lower.
A restatement that still shadows the numbers
Last year's comparative figures were restated after the group identified accounting errors affecting the year ended 31 December 2024, with a total misstated amount of SAR 244 million, and a further SAR 184 million for the year ended 31 December 2025. The restatement included an impairment of reinstated trade receivables of SAR 184.2 million for the comparative nine-month period, with no corresponding charge this year.
The external auditor's report carried a qualified conclusion. The auditors said they were unable to obtain sufficient appropriate review evidence to evaluate certain elements of the restatement and its effects on the comparative financial information. They drew attention, separately, to transactions and balances with related parties provided by entities under common control.
Despite that caution, the auditors stated that nothing had come to their attention suggesting the interim statements were not prepared, in all material respects, in accordance with IAS 34 as endorsed in the Kingdom of Saudi Arabia.
Why Saudi healthcare results matter to the region
The Saudi German Health numbers arrive in a quarter in which listed Gulf healthcare operators have broadly reported strong earnings. Dallah Healthcare posted a 47 percent rise in nine-month profit, according to Jawlah, while Argaam reported that Wataniya's nine-month profit soared to SAR 30.35 million. The pattern points to a regional healthcare sector in robust expansion, driven by privatization programs and rising demand for specialized care.
For Arab investors and observers, the significance goes beyond one company's income statement. Gulf capital markets are becoming the engine of a broader regional economic realignment, one in which Egyptian institutions and investors have a direct stake. Transparency measures like the restatement at Saudi German Health, however uncomfortable, show a market regulator willing to enforce disclosure standards, a discipline that strengthens rather than weakens investor confidence across the Arab world.
Saudi German Health's share price stood at SAR 22.95 at the time of the announcement, down 0.82 percent on the day, suggesting the market had largely priced in the recovery. Total shareholders' equity after deducting minority interests reached SAR 1,536.98 million, up 6.6 percent from SAR 1,441.37 million a year earlier, with earnings per share of SAR 1.14 against SAR 1.05 previously.
Challenges that remain
The results were not without blemishes. The share of loss from the investment in associate Al Sobh Investment Holding Limited widened to SAR 18.5 million from SAR 2.6 million in the comparative period. The company said Al Sobh's profitability is expected to improve gradually, as it commenced operations in the fourth quarter of 2025 and its operational efficiency increases as operations mature.
Higher finance costs resulting from non-cash losses on certain hedging contracts entered into with banks also partially offset the gains. The comparative period had additionally benefited from a one-off gain of SAR 114.5 million on the disposal of an unutilized plot of land in Riyadh, a windfall that did not recur this year.
The prior-year figures were reclassified following the adoption of IFRS 18, adding another layer of complexity to the comparisons. Mergers and acquisitions continue to reshape the sector, as Modern Healthcare's deal tracker documents, and Saudi German Health's push into specialized care positions it within that consolidating landscape.
What happens next
The fourth quarter will show whether the recovery holds. The company's strategy of expanding specialized medical care and surgical services, controlling overhead, and absorbing the costs of its associate investments will be tested as competition intensifies across the Gulf healthcare market.
Frequently Asked Questions
What profit did Saudi German Health report for the first nine months of 2026?
Net profit attributable to shareholders reached SAR 104.49 million for the nine months ended 30 September 2026, up 8.3 percent from SAR 96.46 million a year earlier.
Why did the third quarter swing from loss to profit?
The third quarter of 2025 had been restated to a net loss of SAR 89.66 million, largely because of a SAR 134.2 million impairment of reinstated trade receivables. This year's quarter carried no such charge and benefited from 14.1 percent revenue growth.
What did the auditors say about the results?
The external auditor issued a qualified conclusion, saying it could not obtain sufficient evidence to evaluate certain elements of the restatement of comparative figures, while noting nothing suggesting the statements failed to comply with IAS 34.